P022 Galectin-3, galectin-9, and galectin-3 binding protein in patients with inflammatory bowel diseases
Reads0
Chats0
About:
This article is published in Journal of Crohn's and Colitis.The article was published on 2019-01-25 and is currently open access. It has received 3 citations till now. The article focuses on the topics: Galectin.read more
Citations
More filters
Journal ArticleDOI
Activation of Resolution Pathways to Prevent and Fight Chronic Inflammation: Lessons From Asthma and Inflammatory Bowel Disease.
Cindy Barnig,Tjitske Bezema,Philip C. Calder,Philip C. Calder,Anne Charloux,Nelly Frossard,Johan Garssen,Oliver Haworth,Ksenia Dilevskaya,Francesca Levi-Schaffer,Evelyne Lonsdorfer,Marca H. M. Wauben,Aletta D. Kraneveld,Anje A. te Velde +13 more
TL;DR: The main cells and mediators stimulating the resolution of inflammation are described and how pharmacological and dietary interventions but also life style factors, physical and psychological conditions, might influence the resolution phase are discussed.
Journal ArticleDOI
Altered Bioavailability and Pharmacokinetics in Crohn’s Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs
TL;DR: A meta-analysis of the systems parameters affecting oral drug pharmacokinetics was conducted in this paper , where the information gathered on intestine, liver and blood proteins and other physiological parameters was incorporated into a physiologically based pharmacokinetic (PBPK) platform to create a virtual population of Crohn's disease patients, with a view for guiding dose adjustment in the absence of clinical data in CD.
Journal ArticleDOI
Highlights on the Role of Galectin-3 in Colorectal Cancer and the Preventive/Therapeutic Potential of Food-Derived Inhibitors
TL;DR: A recent review as mentioned in this paper provides an updated summary of preclinical and observational human studies investigating the pathogenetic role of Galectin-3 in intestinal inflammation and colorectal cancer, as well as the potential of Gal-3 activity inhibition by plant-source food-derived bioactive compounds to control CRC onset/growth.